meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis

Sponsor
University Health Network, Toronto
Study ID
NCT05715814
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • End Stage Kidney Disease
  • Kidney Dysfunction
  • Peritoneal Dialysis Complication
  • Residual Kidney Function
  • Sodium-glucose Co-transporter-2 Inhibitors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The primary aim of this study is to determine the safety and mechanisms of SGLT2 inhibition in individuals on peritoneal dialysis (PD) with residual kidney function (RKF).

Key Dates

First listed
Feb 8, 2023
Start date
Sep 1, 2024
Status verified
Apr 2026
Primary completion
May 1, 2027
Completion
Dec 1, 2027

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Empagliflozin

Primary Outcome Measure

Change in measured GFR [ Time Frame: Before and 2 weeks after initiation of empagliflozin. ]

Central Contacts

Related Studies